ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO542

Cost-Effectiveness of a Multiple Intervention Model for Management of CKD in Primary Health-Care

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 307 CKD: Health Services, Disparities, Prevention

Authors

  • Ayala cortes, Rafael Adalid, Unidad de Investigación Médica en Enfermedades Renales, Guadalajara, Jalisco, Mexico
  • Cortes-Sanabria, Laura, Unidad de Investigación Medica en Enfermedades Renales, IMSS, Guadalajara, Jalisco, Mexico
  • Cueto-Manzano, Alfonso M., Unidad de Investigación Medica en Enfermedades Renales, IMSS, Guadalajara, Jalisco, Mexico
  • Rojas-Campos, Enrique, Unidad de Investigación Medica en Enfermedades Renales, IMSS, Guadalajara, Jalisco, Mexico
Background

Strategies to prevent and delay progression of early CKD are urgently needed; however, there is little information about costs and outcomes at the primary health-care. Objective: To evaluate cost-effectiveness of multiple intervention model (MIM) vs conventional health-care model (CHCM) for CKD diagnosis and treatment.

Methods

Prospective evaluation from the health-care provider perspective, performed in 2 Family Medicine Units of Guadalajara, Mexico: MIM and CHCM were evaluated in one unit each. Three phases evaluated: Educative intervention for health professionals, Screening of CKD, and Management/Follow-up of CKD patients. All resources were identified, quantified and recorded; official lists for drugs, medical materials and services, and laboratory/image tests were employed for costs calculation. Only direct medical costs (in USD) were considered. Main outcome and measures: Total cost, average cost per person, and incremental cost-effectiveness ratio (ICER) with bootstrap analysis were determined in each phase. Clinical competence of health professionals was measured with a validated questionnaire, and CKD progression was defined as decline in GFR category.

Results

Clinical competence was not different between models neither at baseline (MIM 63±21 vs CHCM 60±19, p=0.52) nor at final (MIM 94±14 vs CHCM 89±17, p=0.76) evaluations. Average cost per health professional receiving educative intervention in MIM was $833 (CI95% 762-899) vs $901 (819-976) in CHCM (p=0.26). ICER was $22.6 favoring MIM. CKD stages 1-3 were present in 30% of patients from MIM (N 336) and 32% from CHCM (N 454). Average cost per person of CKD screening was $45 (CI95% 41-47) in MIM and $42 (CI95% 37-45) in CHCM (p=0.60). ICER was $2.3 favoring CHCM. For Management/Follow-up phase, 57 patients with CKD stages 1-3 were studied during 12-month in MIM and 58 patients in CHCM. CKD progression was observed in 16% of patients in MIM vs 28% in CHCM (p=0.09). Average cost per patient was $826 (CI95% 760-900) in MIM vs $701 (CI95% 632-777) in CHCM. ICER was dominant in MIM.

Conclusion

MIM are more cost-effective than CHCM to delay kidney disease progression when strategies combining educative interventions for health professionals, screening and adequate management of early CKD are employed at the primary health care.